香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Nanjing Leads Biolabs Co., Ltd. 南 京 維 立志博生物科技股份有限公司 （於 中 華 人 民 共 和 國 成 立 的 股 份 有 限 公 司） （股 份 代 號：9887） 自願公告 LBL-024於一線治療肝細胞癌II期試驗的首例患者用藥 本公告由南京 維 立志博生物科技股份有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，以 告 知 本 公 司 股 東 及 潛 在 投 資 者 有 關 本 公 司 的 最 新 業 務 發 展 情 況。 本 公 司 欣 然 宣 布，評 價 奧 帕 替 蘇 米 單 抗（PD-L1/4-1BB雙特異性抗體LBL-024）用 於一線治療肝細胞癌的II期 臨 床 研 究 首 例 患 者 已 成 功 用 藥，標 誌 著 該 核 心 產 品 適 應 症 拓 展 ...

Core Insights - Crystal Tech Holdings (02228.HK) announced a strategic partnership with Eli Lilly to accelerate the discovery and development of bispecific antibodies for various diseases [1] - The partnership grants Eli Lilly access to Ailux's AI-driven bispecific antibody engineering platform, which integrates advanced structural modeling, generative design, and developmental analysis technologies [1] - The collaboration includes upfront and milestone payments totaling several tens of millions of USD, with potential total milestone payments reaching up to $345 million [1] Company Overview - Ailux Shanghai, a wholly-owned subsidiary of Crystal Tech Holdings, focuses on developing advanced biotherapies using AI-driven solutions [2] - The company has assembled a global team of over 100 members and actively collaborates with leading biopharmaceutical companies to translate cutting-edge scientific achievements into transformative drugs [2] - Crystal Tech Holdings was founded in 2015 by three MIT physicists and operates as an innovative R&D platform leveraging quantum physics, AI, and robotics [2] Financial Performance - In the first half of the year, Crystal Tech Holdings reported a revenue increase of 404% year-on-year, reaching 517 million RMB, with an adjusted net profit of 141 million RMB [3] - Historical revenue figures for Crystal Tech show 62.8 million RMB in 2021, 133 million RMB in 2022, and 80 million RMB in 2023, while net losses were 2.137 billion RMB, 1.439 billion RMB, and 1.906 billion RMB respectively during the same period [3] - The company has raised over 5 billion RMB through eight rounds of financing prior to its IPO, with notable investors including Tencent, Sequoia China, and SoftBank Vision Fund [3] Market Performance - Crystal Tech Holdings has a current market capitalization of 46.26 billion HKD, with a year-to-date increase of nearly 80% [4]

Group 1 - The rise of targeted and immunotherapy has fundamentally reshaped the treatment landscape for lung cancer, with new therapies such as antibody-drug conjugates (ADC), bispecific antibodies, T-cell engagers (TCE), and tumor vaccines emerging rapidly [1] - Fuhong Hanhlin has successfully launched 9 products in the lung cancer field, benefiting over 900,000 patients globally, including the world's first approved PD-1 monoclonal antibody for first-line treatment of small cell lung cancer, which is now available in nearly 40 countries [1] - The company plans to advance at least 8 Phase III clinical studies focused on lung cancer for its product HLX43, which combines the effects of PD-1 and ADC, and aims to expand into other cancers such as cervical, esophageal squamous cell, and colorectal cancers [1] Group 2 - HLX43, as the second ADC targeting PD-L1 globally, has shown promising treatment effects in advanced non-small cell lung cancer (NSCLC), with objective response rates (ORR) of 33.3% in previously treated squamous cell carcinoma patients and 47.4% in EGFR wild-type non-squamous NSCLC patients [2] - The drug demonstrated an ORR of 30% in patients with brain metastases and a disease control rate (DCR) of 90%, indicating its potential effectiveness across various patient subgroups [2] - Safety data for HLX43 indicates low hematological toxicity, providing a solid foundation for subsequent large-scale clinical studies [2]

Group 1 - The 2025 International Lung Cancer Frontier and Innovation Forum was held in Shanghai, focusing on key topics such as clinical prevention and control of lung cancer, breakthroughs in non-small cell lung cancer (NSCLC), and new advancements in immunotherapy for small cell lung cancer (SCLC) [1] - The rise of targeted and immunotherapy has fundamentally reshaped the treatment landscape for lung cancer, with new therapies like antibody-drug conjugates (ADC), bispecific antibodies, T-cell engagers (TCE), and tumor vaccines emerging rapidly [1] - The global incidence of lung cancer remains the highest among malignant tumors, with the company having launched 9 products that benefit over 900,000 patients worldwide, including the first approved PD-1 monoclonal antibody for first-line treatment of SCLC [1] Group 2 - The company's R&D strategy focuses on antibodies and their derivatives, including monoclonal antibodies, bispecific antibodies, multi-specific antibodies, and ADCs, supported by three core technology engines [2] - High-value projects such as HLX3901 and HLX48 are prioritized for future development, while the company continues to build a robust pipeline [2] - Local innovative enterprises have made significant progress over the past decade, providing effective "Chinese solutions" for clinical challenges, emphasizing the need for international collaboration and continuous innovation in tackling lung cancer [2]

Core Viewpoint - Sanofi has granted Pfizer exclusive rights for the development, production, and commercialization of the dual-specific antibody product targeting PD-1 and VEGF, known as project 707, for both human and veterinary uses [1] Group 1: Licensing Agreement - The licensing agreement between Sanofi and Pfizer will officially take effect on July 24, 2025 [1] - The agreement covers all therapeutic, diagnostic, and preventive indications within the licensed area [1] - Payments from Pfizer to Sanofi will be distributed between the company and Shenyang Sanofi [1] Group 2: Clinical Trials - Pfizer has registered two global Phase III clinical trials for the PD-1/VEGF dual antibody PF-08634404 (SSGJ-707) on ClinicalTrials.gov as of October 30, 2025 [1] - The milestone payments outlined in the licensing agreement are contingent upon meeting specific conditions, leading to uncertainty regarding final payments [1]

Core Viewpoint - Sanofi has granted Pfizer exclusive rights for the development, production, and commercialization of the dual-targeting antibody product SSGJ-707, which targets both PD-1 and VEGF, under a licensing agreement that will take effect on July 24, 2025 [1] Group 1: Licensing Agreement Details - The licensing agreement involves a product known as project 707, which is a dual-specific antibody targeting PD-1 and VEGF [1] - All payments made by Pfizer to the licensors will be distributed between the company and Shenyang Sanofi [1] - The agreement includes milestone payments that are contingent upon meeting specific conditions, leading to uncertainty regarding final payments [1] Group 2: Clinical Trials - On October 30, 2025, Pfizer registered two global Phase III clinical trials for the PD-1/VEGF dual antibody PF-08634404 (SSGJ-707) on ClinicalTrials.gov [1]

Core Viewpoint - New Bridge Bio, established in 2016, is a global biotechnology platform company focused on developing innovative precision immuno-oncology drugs for cancer treatment, utilizing a new business model to enhance its drug pipeline through strategic collaborations and specialized subsidiaries [3][4]. Company Overview - New Bridge Bio primarily develops its proprietary drug, givastomig, a bispecific antibody targeting Claudin18.2 and 4-1BB, which is effective against various gastrointestinal malignancies including gastric, esophageal, and pancreatic cancers [3][4]. - The company aims to leverage its new business model to select and advance high-value therapeutic assets through dedicated subsidiaries, enhancing operational focus and risk management [3]. Product Details - Givastomig is designed to target tumors with low Claudin18.2 expression effectively and activates T-cells specifically at the tumor site, potentially reducing systemic side effects associated with traditional therapies [4]. - The global market for first-line treatments for gastric and esophageal adenocarcinoma (GEA), biliary tract cancer (BTC), and pancreatic ductal adenocarcinoma (PDAC) is projected to grow significantly, with estimates of $8.9 billion, $1.8 billion, and $4.4 billion respectively by 2034 [5]. Clinical Development - New Bridge Bio has completed the Phase I clinical study and plans to initiate a randomized Phase II study in early 2026, having received no objections from the FDA regarding its clinical trial plans for givastomig [5]. - The company has established a pipeline that includes three clinical-stage projects, with two focused on oncology and one in ophthalmology [5]. Financial Performance - For the fiscal year 2023, New Bridge Bio reported total revenues of approximately -$202.12 million, with significant operating losses due to high research and administrative expenses [6]. - The company’s revenue from licensing and collaboration was recorded at $632,000 for 2023, with total expenses amounting to $72.65 million [6].

Core Viewpoint - New Bridge Bio has submitted a listing application to the Hong Kong Stock Exchange, with Goldman Sachs and CITIC Securities as joint sponsors [1] Company Overview - New Bridge Bio, established in 2016, is a global biotechnology platform company focusing on developing innovative precision immuno-oncology drugs for cancer treatment [4] - The company aims to enhance its pipeline through strategic collaborations and specialized subsidiaries to better seize market opportunities [4] Product Development - The core product, givastomig, is a novel bispecific antibody targeting Claudin18.2 (CLDN18.2) and T-cell co-stimulatory molecule 4-1BB, applicable to various gastrointestinal malignancies [5] - Givastomig has two main advantages: it can effectively bind to tumors with low CLDN18.2 expression and activates T-cells only after binding to tumor cells, minimizing systemic side effects [5] Market Potential - According to Frost & Sullivan, the global market size for first-line treatments of GEA, BTC, and PDAC (excluding Greater China and South Korea) is estimated at $8.9 billion, $1.8 billion, and $4.4 billion respectively in 2024, projected to reach $13 billion, $2.9 billion, and $6.4 billion by 2034 [7] Clinical Development - New Bridge Bio has completed the safety assessment of the Phase I clinical study and plans to initiate a randomized Phase II study in early 2026 [7] - The company has established a pipeline that includes three clinical-stage projects, with givastomig being a key focus [7] Financial Performance - For the fiscal year ending December 31, 2023, New Bridge Bio reported total revenues of approximately -$202.12 million, with significant operating losses [8] - The company’s total expenses for 2023 were approximately $72.65 million, leading to a substantial operating loss of $72.02 million [8]

的申請版本 香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對 其準確性或完整性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 NovaBridge Biosciences 新橋生物 （根據開曼群島法律註冊成立的有限公司） 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證 監會」）的要求而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。閣下閱覽本文件， 即代表閣下知悉、接納並向新橋生物（「本公司」）、其聯席保薦人、整體協調人、顧問或包 銷團成員表示同意： 本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公司註冊處處長 登記前，本公司不會向香港公眾人士提出要約或邀請。倘於適當時候向香港公眾人士提出 要約或邀請，有意投資者務請僅依據呈交香港公司註冊處註冊的本公司招股章程作出投資 決定；有關文本將於發售期內向公眾刊發。 52791 \ (Project Ion_Redacted) 00b. 警告_Red ...

Core Insights - Roche has entered into a global exclusive collaboration and licensing agreement with Qianxin Biotech for the development, production, and commercialization of QX031N, with a total deal value of up to $1.07 billion [1][2][10] Group 1: Product Overview - QX031N is a long-acting bispecific antibody targeting TSLP and IL-33, proteins involved in respiratory diseases such as COPD and asthma [2][3] - The potential market for QX031N is significant, with nearly 100 million COPD patients in China and an increasing prevalence of asthma, affecting approximately 45.7 million individuals aged 20 and above [3] Group 2: Company Performance - Qianxin Biotech reported a revenue of RMB 206.5 million for the six months ending June 30, 2025, a year-on-year increase of 359.69%, while the loss for the period was reduced by 83.11% to RMB 30.9 million [6][7] - The company has established a leading integrated antibody drug development platform, which supports the efficient discovery and development of differentiated candidate molecules [4] Group 3: Market Position and Future Prospects - The company has one approved product, QX001S, a biosimilar to ustekinumab, and aims to commercialize three self-developed products by 2027 [8][9] - The revenue for the first half of the year was primarily driven by licensing agreements, including upfront payments and milestone fees related to QX030N and QX004N [9]